PRODRUGS OF STAT3 INHIBITORS
Provided herein, in certain embodiments, are compounds of Formula I: or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
1 . A compound of Formula I:
or a pharmaceutically acceptable salt or a solvate thereof, wherein
A is halo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, or C 1-4 haloalkoxy;
R 1 , R 2 , and R 3 are each independently H, C(═O)NR A R B , P(═O)(OH)(R C ), or C 1-4 alkylene-O—P(═O)(OH)(R C ); or
R 1 and R 2 together form:
provided that R 1 , R 2 and R 3 are not simultaneously H;
R A is H or C 1-4 alkyl;
R B is C 1-6 alkylene-N(H)(C 1-6 alkyl), C 1-6 alkylene-(5-8 membered heterocyclyl), C 1-6 alkylene-C(═O)OH optionally substituted with amine, C 1-4 alkyl, or benzyl;
R C is C 1-4 alkyl or hydroxy; and
n is an integer 0, 1, 2, or 3.
2 . The compound of claim 1 , wherein R 3 is H.
3 . The compound of claim 1 , wherein R 3 is C(═O)NR A R B .
4 . The compound of any one of claims 1-3 , wherein R 1 is H.
5 . The compound of any one of claims 1-3 , wherein R 1 and R 2 together form:
6 . The compound of any one of claims 1-4 , wherein R 2 is C(═O)NR A R B .
7 . The compound of any one of claims 1-4 , wherein R 2 is P(═O)(OH)(R c ).
8 . The compound of any one of claims 1-4 , wherein R 2 is C 1-4 alkylene-O—P(═O)(OH)(R c ).
9 . The compound of any one of claims 1-8 , wherein n is 0 or 1.
10 . The compound of any one of claims 1-9 , wherein n is 1.
11 . The compound of claim 1 , wherein the compound is a compound of Formula I-A:
or a pharmaceutically acceptable salt or a solvate thereof.
12 . The compound of claim 11 , wherein A is C 1-4 alkoxy.
13 . The compound of claim 12 , wherein the compound is a compound of Formula I-G:
or a pharmaceutically acceptable salt or a solvate thereof.
14 . The compound of claim 13 , wherein the compound is a compound of Formula I-H or Formula I-K:
or a pharmaceutically acceptable salt or a solvate thereof.
15 . The compound of claim 13 , wherein the compound is a compound of Formula I-I or Formula I-L:
or a pharmaceutically acceptable salt or a solvate thereof.
16 . The compound of claim 1 , wherein the compound is a compound of Formula I-J:
or a pharmaceutically acceptable salt or a solvate thereof.
17 . The compound of claim 1 , wherein the compound is:
or pharmaceutically acceptable salts or solvates thereof.
18 . A pharmaceutical composition comprising: a) a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, and b) a pharmaceutically acceptable carrier.
19 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating cancer in an individual in need thereof.
20 . The compound for use of claim 19 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, skin cancer, kidney cancer, testicular cancer, colon cancer, rectal cancer, gastric cancer, metastatic melanoma, prostate cancer, ovarian cancer, cervical cancer, bone cancer, spleen cancer, gall bladder cancer, brain cancer, pancreatic cancer, stomach cancer, anal cancer, multiple myeloma, post-transplant lymphoproliferative disease, restenosis, myelodysplastic syndrome, leukemia, or lymphoma.
21 . The compound for use of claim 19 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, leukemia, or pancreatic cancer.
22 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating fibrosis in an individual in need thereof.
23 . The compound for use of claim 22 , wherein fibrosis is pulmonary fibrosis, bone marrow fibrosis, intestine fibrosis, pancreatic fibrosis, joint fibrosis, liver fibrosis, retroperitoneum fibrosis, renal fibrosis, myelofibrosis, dermal fibrosis, or systemic sclerosis.
24 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating inflammatory disease or disorder in an individual in need thereof.
25 . The compound for use of claim 24 , wherein the inflammatory disease or disorder is inflammatory bowel disease, ulcerative colitis, psoriasis, uveitis, scleritis, multiple sclerosis, pancreatitis, or asthma.
26 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating neurodegenerative disease or disorder in an individual in need thereof.
27 . The compound for use of claim 26 , wherein the neurodegenerative disease or disorder is chemotherapy-induced peripheral neuropathy, diabetic neuropathy, or familial amyloid polyneuropathy.
28 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating non-alcoholic fatty liver disease or steatohepatitis in an individual in need thereof.
29 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating cachexia in an individual in need thereof.
30 . A compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, for use in a method of treating anaphylaxis in an individual in need thereof.
31 . A method of treating cancer in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .
32 . The method of claim 31 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, skin cancer, kidney cancer, testicular cancer, colon cancer, rectal cancer, gastric cancer, metastatic melanoma, prostate cancer, ovarian cancer, cervical cancer, bone cancer, spleen cancer, gall bladder cancer, brain cancer, pancreatic cancer, stomach cancer, anal cancer, multiple myeloma, post-transplant lymphoproliferative disease, restenosis, myelodysplastic syndrome, leukemia, or lymphoma.
33 . The method of claim 31 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, leukemia, or pancreatic cancer.
34 . A method of treating fibrosis in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .
35 . The method of claim 34 , wherein fibrosis is pulmonary fibrosis, bone marrow fibrosis, intestine fibrosis, pancreatic fibrosis, joint fibrosis, liver fibrosis, retroperitoneum fibrosis, renal fibrosis, myelofibrosis, dermal fibrosis, or systemic sclerosis.
36 . A method of treating inflammatory disease or disorder in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .
37 . The method of claim 36 , wherein the inflammatory disease or disorder is inflammatory bowel disease, ulcerative colitis, psoriasis, uveitis, scleritis, multiple sclerosis, pancreatitis, or asthma.
38 . A method of treating neurodegenerative disease or disorder in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .
39 . The method of claim 38 , wherein the neurodegenerative disease or disorder is chemotherapy-induced peripheral neuropathy, diabetic neuropathy, or familial amyloid polyneuropathy.
40 . A method of treating non-alcoholic fatty liver disease or steatohepatitis in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .
41 . A method of treating cachexia in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .
42 . A method of treating anaphylaxis in an individual in need thereof, comprising administering to the individual an effective amount of a compound of any one of claims 1-17 , or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition of claim 18 .